
Milestone Pharmaceuticals Inc. (MIST) Stock Ticker
Market factors today
Unlock the full MIST picture
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
MIST stock facts
| Ticker symbol | MIST |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $98.2M |
| CEO | Joseph G. Oliveto |
| Employees | 38 |
| Headquarters | Montreal, QC, CA |
| IPO date | 2019-05-09 |
| Website | www.milestonepharma.com |
What you can see for MIST on Tickr
Live MIST price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MIST report.
Rankings
FAQ
What is the ticker symbol for Milestone Pharmaceuticals Inc.?
The ticker symbol for Milestone Pharmaceuticals Inc. is MIST, listed on the NASDAQ Global Select.
What is MIST?
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the…